Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C
- PMID: 31506181
- DOI: 10.1016/j.radonc.2019.08.009
Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C
Abstract
Background and purpose: Systemic therapy such as sorafenib is the standard for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC); however, the survival benefits are modest especially for HCC with macroscopic vascular invasion (MVI). Transarterial chemoembolization (TACE) plus external beam radiotherapy (RT) is an alternative treatment to sorafenib, with favorable clinical results. We evaluated the outcomes of respiratory-gated RT and TACE in treatment-naïve BCLC stage C HCC patients with MVI and proposed a subclassification model.
Methods: In this study, 639 patients received TACE plus RT for HCC with MVI as a first-line treatment between January 2010 and December 2015.
Results: Main/bilateral portal vein and/or inferior vena cava tumor thrombus was observed in 353 (55.2%) patients. The median radiation dose was 39 Gy (range 24-50) with a 2.5-Gy (2-5) median fraction size. The median overall survival was 10.7 months, with 1- and 2-year survival rates of 46.5% and 23.9%, respectively. In the multivariate analysis, Child-Pugh classification B, tumor size >10 cm, infiltrative/diffuse type, presence of extrahepatic metastasis, alpha-fetoprotein >150,000 ng/mL, and radiation dose ≤40 Gy were significant predictors for poor overall survival. Subclassification of patients into very low, low, intermediate, and high-risk groups showed median survivals of 84.8, 14.7, 10.3, and 5.7 months, respectively (p < 0.001).
Conclusion: TACE plus RT is an effective and safe treatment for HCC with MVI and could be considered a first-line treatment option. The subclassification scheme accurately predicted the prognosis of these patients and may be useful for tailored treatment.
Keywords: Hepatocellular carcinoma; Radiotherapy; Subclassification; Transarterial chemoembolization; Vascular invasion.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.JAMA Oncol. 2018 May 1;4(5):661-669. doi: 10.1001/jamaoncol.2017.5847. JAMA Oncol. 2018. PMID: 29543938 Free PMC article. Clinical Trial.
-
Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.Radiology. 2019 Jul;292(1):237-247. doi: 10.1148/radiol.2019181818. Epub 2019 May 28. Radiology. 2019. PMID: 31135299
-
Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment.Medicine (Baltimore). 2017 Apr;96(17):e6745. doi: 10.1097/MD.0000000000006745. Medicine (Baltimore). 2017. PMID: 28445298 Free PMC article.
-
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.World J Gastroenterol. 2015 Sep 28;21(36):10327-35. doi: 10.3748/wjg.v21.i36.10327. World J Gastroenterol. 2015. PMID: 26420959 Free PMC article. Review.
-
Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.Hepatol Int. 2018 Sep;12(5):417-428. doi: 10.1007/s12072-018-9888-4. Epub 2018 Aug 2. Hepatol Int. 2018. PMID: 30073454
Cited by
-
Complete Response of Hepatocellular Carcinoma With Inferior Vena Cava Tumor Thrombus and Right Atrium Involvement to Combined Radiotherapy and Immunotherapy: A Case Report.Gastro Hep Adv. 2025 Feb 1;4(5):100634. doi: 10.1016/j.gastha.2025.100634. eCollection 2025. Gastro Hep Adv. 2025. PMID: 40470485 Free PMC article.
-
Hypofractionated Radiotherapy for Palliation of Main Portal Vein Tumor Thrombosis.Front Oncol. 2022 Apr 27;12:882272. doi: 10.3389/fonc.2022.882272. eCollection 2022. Front Oncol. 2022. PMID: 35574374 Free PMC article.
-
Sorafenib combined with radiation therapy for advanced hepatocellular carcinoma with portal and hepatic vein invasion extending to the inferior vena cava: a complete response case according to modified RECIST criteria.J Liver Cancer. 2022 Mar;22(1):63-68. doi: 10.17998/jlc.2022.01.18. Epub 2022 Feb 14. J Liver Cancer. 2022. PMID: 37383539 Free PMC article.
-
Hepatocellular Carcinoma With Different Areas of Right Retroperitoneal Space Invasion: Evaluation of Transcatheter Arterial Chemoembolization Efficacy and Blood Supply Characteristics.Front Oncol. 2020 Sep 23;10:539692. doi: 10.3389/fonc.2020.539692. eCollection 2020. Front Oncol. 2020. PMID: 33072569 Free PMC article.
-
Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective.Korean J Radiol. 2021 Nov;22(11):1822-1833. doi: 10.3348/kjr.2021.0229. Epub 2021 Aug 19. Korean J Radiol. 2021. PMID: 34431250 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous